ReviewCurrent hypertension reports2007
The vasodilatory beta-blockers.
Review in Current hypertension reports, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 2 syntheses or guidelines pooled it, 145 citations in OpenAlex.
- Beta-blockers for hypertension.The Cochrane database of systematic reviews · 2017Pooled it
- 7th Brazilian Guideline of Arterial Hypertension: Chapter 7 - Pharmacological TreatmentArquivos brasileiros de cardiologia · 2016Guideline
- Additivity of nebivolol/valsartan single-pill combinations versus other single-pill combinations for hypertension.Journal of clinical hypertension (Greenwich, Conn.) · 2018Trial
- The efficacy and tolerability of nebivolol in hypertensive African American patients.Journal of clinical hypertension (Greenwich, Conn.) · 2007Trial
- Drug-induced hyperglycemia in obstetrics: key offending drugs, mechanisms, and practical management.Frontiers in pharmacology · 2026Review
- Analysis of Personalized Cardiovascular Drug Therapy: From Monitoring Technologies to Data Integration and Future Perspectives.Biosensors · 2025Review
- β-blockers and metabolic modulation: unraveling the complex interplay with glucose metabolism, inflammation and oxidative stress.Frontiers in pharmacology · 2024Review
- Beta-Blockers and Hypertension: Some Questions and Answers.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2023Review
- Effects of β-blockers therapy on the 28-day and 3-year survival rates of end-stage renal disease patients with cardiovascular disease: a retrospective cohort study.Annals of translational medicine · 2022Article
- Mechanisms and Clinical Implications of Endothelial Dysfunction in Arterial Hypertension.Journal of cardiovascular development and disease · 2022Review
- Pharmacological differences between beta-blockers and postoperative mortality following colon cancer surgery.Scientific reports · 2022Article
- Nebivolol: an effective option against long-lasting dyspnoea following COVID-19 pneumonia - a pivotal double-blind, cross-over controlled study.Multidisciplinary respiratory medicine · 2022Article
- Beta-adrenergic receptor blockade in angiosarcoma: Which beta-blocker to choose?Frontiers in oncology · 2022Article
- The effect of beta-blockers on hemodynamic parameters in patient-specific blood flow simulations of type-B aortic dissection: a virtual study.Scientific reports · 2021Article
- Berries and Their Polyphenols as a Potential Therapy for Coronary Microvascular Dysfunction: A Mini-Review.International journal of molecular sciences · 2021Review
- Brazilian Guidelines of Hypertension - 2020.Arquivos brasileiros de cardiologia · 2021Article
- Comparison of the Apnea-Hypopnea Index Determined by a Peripheral Arterial Tonometry-Based Device With That Determined by Polysomnography - Results From a Multicenter Study.Circulation reports · 2020Article
- Epidural anesthesia and hypotension in pheochromocytoma and paraganglioma.Endocrine-related cancer · 2020Article
- The Effect of Nebivolol on Office Blood Pressure of Blacks Residing in Sub-Saharan Africa (A Pilot Study).Frontiers in cardiovascular medicine · 2020Article
- Risk of Hospitalization for Cardiovascular Events with β-Blockers in Hypertensive Patients: A Retrospective Cohort Study.Cardiology and therapy · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although well established in treating hypertension and cardiovascular (CV) disease, clinical trial data suggest that beta-blockers (eg, atenolol) may be less effective than other antihypertensive classes in reducing stroke and CV mortality despite similar blood pressure (BP) reductions. One possible explanation is that atenolol is less effective in reducing central aortic pressure. Newer vasodilating beta-blockers may prove more effective in reducing central pressure and cardiovascular events. Carvedilol and labetalol appear to cause vasodilation through alpha(1)-receptor blockade; nebivolol induces endothelium-dependent vasodilation by stimulating nitric oxide bioactivity. Their favorable hemodynamic profile includes reduction of peripheral vascular resistance (PVR) while maintaining or improving cardiac output (CO), stroke volume, and left ventricular function, whereas nonvasodilating beta-blockers tend to raise PVR and reduce CO and left ventricular function. Compared with conventional beta-blockers, vasodilating beta-blockers have beneficial hemodynamic effects including decreased pressure wave reflection from the periphery, leading to decreases in central aortic blood pressure. Larger trials are needed to determine whether reduced central pressure will translate into improved CV outcomes compared with nonvasodilating beta-blockers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.